News
PHAR
--
0.00%
--
The Daily Biotech Pulse: Osmotica Faces Second FDA Rejection, UK Conditionally Approves AstraZeneca's Vaccine Candidate, Hepion NASH Data
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Dec. 29)
Benzinga · 12/30/2020 13:08
The Daily Biotech Pulse: FDA Nod For Amphastar's Generic Glucagon, Arcturus Sinks On Vaccine Data, Decision Day For Osmotica
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Dec. 28)
Benzinga · 12/29/2020 13:09
BRIEF-Pharming Group Q1 Operating Profit Up At 19.4 Million Euros
* PHARMING GROUP REPORTS FINANCIAL RESULTS FOR THE FIRST QUARTER OF 2020
Reuters · 05/14/2020 06:12
BRIEF-Pharming Group: EC Approves Ruconest For Treatment Of HAE Attacks In Children
* RECEIVES EUROPEAN COMMISSION APPROVAL FOR TREATMENT OF ACUTE HEREDITARY ANGIOEDEMA ATTACKS IN CHILDREN WITH RUCONEST
Reuters · 04/30/2020 06:40
BRIEF-Pharming Enters Euronext Amsterdam Midkap Index
* DESPITE UNCERTAINTY AROUND COVID-19, FOR NOW, WE DO NOT ANTICIPATE ANY ISSUES WITH REGARDS TO CONTINUOUS SUPPLY OF RUCONEST AND WE REMAIN CONFIDENT IN LONG-TERM PROSPECTS OF BUSINESS Source text for Eikon: Further company coverage: (Gdansk Newsroom)
Reuters · 03/23/2020 06:08
BRIEF-Pharming CFO Robin Wright To Step Down
* ROBIN WRIGHT, HAS DECIDED (FOR FAMILY REASONS) NOT TO PUT HIMSELF UP FOR RE-ELECTION AS A MEMBER OF BOARD OF MANAGEMENT AND THUS AS CHIEF FINANCIAL OFFICER
Reuters · 03/11/2020 06:22
BRIEF-Pharming Group Receives FDA Approval Of New Facility For Expansion Of Ruconest® Production
* PHARMING GROUP NV SAYS RECEIVES FDA APPROVAL OF NEW FACILITY FOR EXPANSION OF RUCONEST® PRODUCTION
Reuters · 03/09/2020 06:11
BRIEF-Pharming Group FY Net Profits Up At 36.2 Million Euros
* FULL YEAR NET PROFITS WERE EUR 36.2 MILLION ($40.5 MILLION), AN INCREASE OF 45% ON 2018
Reuters · 03/05/2020 06:15
BRIEF-Pharming Enters Euronext Amsterdam SmallCap-Index (AScX)
* PHARMING ENTERS THE EURONEXT AMSTERDAM SMALLCAP-INDEX (ASCX) Source text for Eikon: Further company coverage: (Gdynia Newsroom)
Reuters · 03/15/2018 06:23
BRIEF-Pharming Group Q4 Revenues From Product Sales OF EUR 32.7 Mln, Up 26 Pct Vs. Q3
* DELIVERED REVENUE FOR FULL YEAR OF EUR 89.6 MILLION (US$101.2 MILLION) - AN INCREASE OF 464% ON 2016
Reuters · 03/07/2018 06:18
BRIEF-Pharming Announces FDA Acceptance For Review Of Supplemental Biologics License Application
* PHARMING ANNOUNCES FDA ACCEPTANCE FOR REVIEW OF SUPPLEMENTAL BIOLOGICS LICENSE APPLICATION FOR RUCONEST® FOR PROPHYLAXIS OF HEREDITARY ANGIOEDEMA ATTACKS
Reuters · 01/17/2018 06:26
BRIEF-Pharming Group Announces Further Conversion Of Ordinary Convertible Bonds
* BONDHOLDERS CONVERT €7.7 MILLION OF THEIR REMAINING BONDS INTO PHARMING SHARES AND CASH
Reuters · 01/04/2018 06:13
Webull provides a variety of real-time PHAR stock news. You can receive the latest news about Pharming Group N.V. through multiple platforms. This information may help you make smarter investment decisions.
About PHAR
Pharming Group NV is a biopharmaceutical company based in the Netherlands. The Company is engaged in the development, production and commercialization of human therapeutic proteins to be used in the therapies. The Company's product portfolio is aimed at treatments for genetic disorders, blood-related disorders, infectious and inflammatory diseases, tissue and bone damage and surgical/traumatic bleeding. Its core product, RUCONEST (conestat alfa) is a recombinant human C1 esterase inhibitor approved for the treatment of acute Hereditary Angioedema (HAE) attacks in patients in Europe, the Unites States, Israel and South Korea. The product is available on a named-patient basis in other territories where it has not yet obtained marketing authorization.
More